Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Express Scripts
Harvard Business School
Moodys
McKesson

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR MESALAMINE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Mesalamine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00063414 ↗ ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis Completed Ionis Pharmaceuticals, Inc. Phase 2 1969-12-31 This is a multi-center trial to test the safety, efficacy and tolerability of alicaforsen (ISIS 2302), a new type of drug called an antisense drug, in patients with mild to moderate active Ulcerative Colitis (UC). Alicaforsen is designed to reduce the production of a specific protein, called ICAM-1, a substance that plays a significant role in the increase of inflammation and is likely to be involved in inflammatory bowel diseases such as ulcerative colitis. The ISIS 2302-CS22 study will examine the effects of one of two dosages of alicaforsen delivered by enema over a six-week period as compared to an active control, mesalamine enema (The probability of receiving the alicaforsen formulation is 2:1). The primary objective of this study is to evaluate the percentage reduction in DAI at Week 6.
NCT00098111 ↗ Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease Terminated Massachusetts General Hospital Phase 3 2005-04-01 The purpose of this study is to identify an optimal weight based dose of azathioprine that is safe and effective in the treatment of subjects with active Crohn's disease requiring treatment with corticosteroids, and for maintaining remission in those subjects.
NCT00109473 ↗ Trial of Growth Hormone Therapy in Pediatric Crohn's Disease Completed Genentech, Inc. Phase 2 2005-04-01 The purpose of this study is to determine whether taking a growth hormone (GH) drug called somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when compared to a person with Crohn's Disease that does not receive growth hormone drug.
NCT00109473 ↗ Trial of Growth Hormone Therapy in Pediatric Crohn's Disease Completed Children's Hospital Medical Center, Cincinnati Phase 2 2005-04-01 The purpose of this study is to determine whether taking a growth hormone (GH) drug called somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when compared to a person with Crohn's Disease that does not receive growth hormone drug.
NCT00151892 ↗ Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis Completed Shire Phase 3 2005-04-08 Ulcerative colitis is a disease of the large bowel (colon) and rectum in which the lining of the bowel becomes red and swollen. Over time, patients with this disease may experience acute episodes of diarrhea, rectal bleeding and abdominal pain followed by periods of time without disease symptoms. 5-ASA drugs are a standard treatment for ulcerative colitis. Mesalazine is an experimental drug designed to gradually release 5-ASA into the areas of large bowel associated with ulcerative colitis. This study will test the safety and efficacy of mesalazine in keeping ulcerative colitis in remission.
NCT00194818 ↗ Asacol Dosing Study for Active Ulcerative Colitis Completed Procter and Gamble Phase 4 2003-06-01 We, the investigators at University of Washington, plan on evaluating the effect of open label Asacol at a dose of 4.8 grams/day divided BID (twice per day) or TID (three times per day) on its ability to induce remission in patients with mild to moderately active ulcerative colitis. We hypothesize that both regimens will have the same efficacy and no difference in side effects.
NCT00194818 ↗ Asacol Dosing Study for Active Ulcerative Colitis Completed University of Washington Phase 4 2003-06-01 We, the investigators at University of Washington, plan on evaluating the effect of open label Asacol at a dose of 4.8 grams/day divided BID (twice per day) or TID (three times per day) on its ability to induce remission in patients with mild to moderately active ulcerative colitis. We hypothesize that both regimens will have the same efficacy and no difference in side effects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mesalamine

Condition Name

Condition Name for Mesalamine
Intervention Trials
Ulcerative Colitis 37
Healthy 10
Crohn's Disease 5
Inflammatory Bowel Disease 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mesalamine
Intervention Trials
Colitis 52
Colitis, Ulcerative 51
Ulcer 46
Crohn Disease 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mesalamine

Trials by Country

Trials by Country for Mesalamine
Location Trials
United States 432
Canada 34
India 28
Poland 22
Italy 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mesalamine
Location Trials
Florida 23
Texas 21
California 21
Georgia 18
New York 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mesalamine

Clinical Trial Phase

Clinical Trial Phase for Mesalamine
Clinical Trial Phase Trials
Phase 4 11
Phase 3 29
Phase 2/Phase 3 2
[disabled in preview] 46
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mesalamine
Clinical Trial Phase Trials
Completed 57
Terminated 16
Not yet recruiting 7
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mesalamine

Sponsor Name

Sponsor Name for Mesalamine
Sponsor Trials
Shire 11
Bausch Health Americas, Inc. 8
Valeant Pharmaceuticals International, Inc. 8
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mesalamine
Sponsor Trials
Industry 74
Other 66
NIH 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Merck
Colorcon
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.